clinical trial · NCT06039449
A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2
COVID-19SARS-CoV-2VYD222 (pemivibart)Normal saline
brief summary
A study to investigate the prevention of COVID-19 with VYD222 in adults with immune compromise and in participants aged 12 years or older who are at risk of exposure to SARS-CoV-2
started
Sep 8, 2023
primary completion
Nov 19, 2024
completion
Nov 19, 2024
last updated
Dec 9, 2024
official title
A Study to Evaluate the Efficacy and Safety of VYD222 for Prevention of COVID-19 (CANOPY)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol